Mutation Analysis of Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer for Selection of Patients Eligible for Tyrosine Kinase Inhibitor Therapy
, und
23. Jan. 2024
Über diesen Artikel
Artikel-Kategorie: Original Article
Online veröffentlicht: 23. Jan. 2024
Seitenbereich: 1 - 9
Eingereicht: 03. Aug. 2023
Akzeptiert: 08. Dez. 2023
DOI: https://doi.org/10.37029/jcas.v10i1.569
Schlüsselwörter
© 2024 Zeeshan Ansar et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Figure 1:
![Algorithm for histopathological diagnosis. It has been adapted from Ahmed et al.[11]](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/67d1794c8d1bec042eab8a65/j_jcas.v10i1.569_fig_001.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=AKIA6AP2G7AKOUXAVR44%2F20250910%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Date=20250910T194153Z&X-Amz-Expires=3600&X-Amz-Signature=c60fdee74da478b362d30c5be0e78a551571a4d49abcf2cfced3061e7c94b8c0&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)
Figure 2:
Lists the epidermal growth factor receptor mutations detected by the cobas EGFR test_ The list has been adapted from the cobas EGFR mutation test v2 kit insert available on https://diagnostics_roche_com/us/en/products/params/cobas-egfr-mutation-test-v2_html
| Exon | EGFR mutation group | EGFR nucleic acid sequence |
|---|---|---|
| Exon 18 | G719X | 2156G>C |
| 2155G>A | ||
| 2155G>T | ||
| Exon 19 | E×19Del | 2240_2251del12 |
| 2239_2247del9 | ||
| 2238_2255del18 | ||
| 2235_2249del15 | ||
| 2236_2250del15 | ||
| 2239_2253del15 | ||
| 2239_2256del18 | ||
| 2237_2254del18 | ||
| 2240_2254del15 | ||
| 2240_2257del18 | ||
| 2239_2248TTAAGAGAAG>C | ||
| 2239_2251>C | ||
| 2237_2255>T | ||
| 2235_2255>AAT | ||
| 2237_2252>T | ||
| 2239_2258>CA | ||
| 2239_2256>CAA | ||
| 2237_2253>TTGCT | ||
| 2238_2252>GCA | ||
| 2238_2248>GC | ||
| 2237_2251del15 | ||
| 2236_2253del18 | ||
| 2235_2248>AATTC | ||
| 2235_2252>AAT | ||
| 2235_2251>AATTC | ||
| 2253_2276del24 | ||
| 2237_2257>TCT | ||
| 2238_2252del15 | ||
| 2233_2247del15 | ||
| Exon 20 | S768I | 2303G>T |
| T790M | 2369C>T | |
| E×20Ins | 2307_2308ins9GCCAGCGTG | |
| 2319_2320insCAC | ||
| 2310_2311insGGT | ||
| 2311_2312ins9GCGTGGACA | ||
| 2309_2310AC>CCAGCGTGGAT | ||
| Exon 21 | L858R | 2573T>G |
| 2573_2574TG>GT | ||
| L861Q | 2582T>A |
EGFR mutation status by gender and age groups
| Variable | EGFR mutation | Total | ||
|---|---|---|---|---|
| Positive | Negative | |||
| Gender | ||||
| Male | 92 (20%) | 374 (80%) | 466 | |
| Female | 79 (37%) | 137 (63%) | 216 | |
| Age | ||||
| Male≤50 years | 25 (25%) | 76 (75%) | 101 | NS |
| Male>50 years | 67 (18%) | 298 (82%) | 365 | |
| Female≤50 years | 15 (22%) | 54 (78%) | 69 | |
| Female>50 years | 64 (44%) | 83 (56%) | 147 | |
Patients demographic and histopathological features
| Variable | Characteristics | No. (%) |
|---|---|---|
| Gender | Male | 466 (68.3%) |
| Female | 216 (31.7%) | |
| Age (years) | Male | Range 5–90 Mean age (60.7) |
| Female | Range 6–91 Mean age (55.9) | |
| EGFR mutation status | Positive | 171 (25%) |
| Negative | 511 (75%) | |
| Histopathology | Adenocarcinoma | 649 (95%) |
| Squamous cell carcinoma | 11 (1.6%) | |
| Other (metastatic malignancy of unknown/undefined primary origin) | 22 (3.4%) |
EGFR mutation status by histopathological characteristics
| Histopathology | EGFR mutation | Total | ||
|---|---|---|---|---|
| Positive | Negative | |||
| Adenocarcinoma | 82 (27%) | 226 (73%) | 308 | NS |
| Poorly differentiated adenocarcinoma | 14 (20%) | 53 (80%) | 67 | |
| Moderately differentiated adenocarcinoma | 13 (23%) | 43 (77%) | 56 | |
| Well-differentiated adenocarcinoma | 8 (42%) | 11 (58%) | 19 | |
| Metastatic adenocarcinoma | 55 (27%) | 144 (73%) | 199 | |
| Squamous cell carcinoma | 3 (27%) | 8 (73%) | 11 | |